GlassScriptPhysician profile
Iosif Kalendarev
NPI 1457720963
$3,496.96
in general payments reported to CMS, 2019-2025
20 companies · $1,121 in 2025
The $1,121 reported for 2025 was more than what 86% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $108 · 2022: $515 · 2023: $757 · 2024: $995 · 2025: $1,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,873.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,873.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $896.03 | 2021-2025 | |
| Blueprint Medicines Corporation | $649.91 | 2022-2025 | Ayvakit |
| Takeda Pharmaceuticals U.S.A., INC. | $322.27 | 2024-2025 | Iclusig |
| Celgene Corporation | $262.46 | 2022-2025 | Reblozyl |
| Glaxosmithkline, LLC. | $260.18 | 2023-2025 | Ojjaara, Shingrix |
| Abbvie INC. | $190.08 | 2023-2024 | |
| Kite Pharma, INC. | $166.52 | 2024-2025 | Yescarta |
| Amgen INC. | $161.08 | 2021-2023 | Blincyto |
| Genzyme Corporation | $156.33 | 2025 | |
| Rigel Pharmaceuticals, INC. | $103.50 | 2023-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Servier Pharmaceuticals LLC | $68.62 | 2023-2025 | |
| Azurity Pharmaceuticals, INC. | $53.36 | 2025 | Danziten |
| Bayer Healthcare Pharmaceuticals INC. | $42.81 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $30.39 | 2023 | Reblozyl |
| Incyte Corporation | $29.16 | 2025 | Niktimvo, Jakafi |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $28.38 | 2025 | Vanflyta |
| Stemline Therapeutics INC. | $24.31 | 2025 | Elzonris |
| Pfizer INC. | $19.05 | 2025 | |
| Sanofi-Aventis U.S. LLC | $16.59 | 2025 | |
| Merck Sharp & Dohme LLC | $15.93 | 2023 | Keytruda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iosif Kalendarev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.